# Petmed Express Inc: Form 10-Q for the period ended Sep 30, 2021

- Company: [Petmed Express Inc](/companies/pets.md) (CIK 1040130)
- Form: 10-Q
- Filed: 2021-11-02
- Accepted by EDGAR: Nov 2, 2021, 14:39 ET
- Period: 2021-09-30
- Accession: 0001437749-21-024890
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1040130/000143774921024890/pets20210930_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1040130/000143774921024890/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $67.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months, 2021-04-01 to 2021-09-30 | $146.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $48.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-04-01 to 2021-09-30 | $105.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | $19.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-04-01 to 2021-09-30 | $41.0m | us-gaap:GrossProfit |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | $8.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-04-01 to 2021-09-30 | $13.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | $2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-04-01 to 2021-09-30 | $3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | $6.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-04-01 to 2021-09-30 | $10.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-04-01 to 2021-09-30 | $0.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-04-01 to 2021-09-30 | $0.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 20,568,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-04-01 to 2021-09-30 | 20,384,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-04-01 to 2021-09-30 | $1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-04-01 to 2021-09-30 | $972.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2021-04-01 to 2021-09-30 | $12.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2021-09-30 | $106.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $133.4m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $159.4m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $16.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $17.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $141.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 24,461 characters.

### Executive Summary

PetMed Express was incorporated in the state of Florida in January 1996. The Company’s common stock is traded on the NASDAQ Global Select Market under the symbol “PETS.” The Company began selling pet medications and other pet health products in September 1996. In March 2010, the Company started offering for sale additional pet supplies on its website, and these items are drop shipped to customers by third party vendors. Presently, the Company’s product line includes approximately 3,000 SKUs of the most popular pet medications, health products, and supplies for dogs, cats, and horses.

The Company markets its products through national advertising campaigns which aim to increase the recognition of the “PetMeds” brand name, increase traffic on its website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Approximately 83% of all sales were generated via the Internet for both the quarters ended September 30, 2021 and 2020. The Company’s sales consist of products sold mainly to retail consumers. The three-month average purchase was approximately $92 and $87 per order for the quarters ended September 30, 2021 and 2020, respectively, and the six-month average purchase was approximately $93 and $88 per order for the six months ended September 30, 2021 and 2020, respectively.

### Critical Accounting Policies

Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our Condensed Consolidated Financial Statements and the data used to prepare them. The Company’s Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

Revenue recognition

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however it is not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

Outbound shipping and handling fees are an accounting policy election, and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales.

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card charge-backs or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $28,000 at September 30, 2021 compared to $39,000 at March 31, 2021.

Valuation of inventory

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or market value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $49,000 at September 30, 2021 compared to $86,000 at March 31, 2021.

Advertising

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related brochures and postcards are produced, distributed, or superseded. Television advertising costs are expensed in the month advertisements are televised.

Accounting for income taxes

The Company accounts for income taxes under the provisions of ASC Topic 740 (“*Accounting for Income Taxes”*), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the Company’s Condensed Consolidated Financial Statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities, and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

### Results of Operations

The following should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in the Company’s Condensed Consolidated Statements of Income:

|  | Three Months Ended September 30, 2021 | 2020 | Six Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | 71.5 | 69.5 | 72.1 | 71.0 |
| Gross profit | 28.5 | 30.5 | 27.9 | 29.0 |
| Operating expenses: |  |  |  |  |
| General and administrative | 10.4 | 9.0 | 10.2 | 8.4 |
| Advertising | 5.1 | 6.8 | 7.6 | 8.3 |
| Depreciation | 1.0 | 0.8 | 0.9 | 0.7 |
| Total operating expenses | 16.5 | 16.6 | 18.7 | 17.4 |
| Income from operations | 12.0 | 13.9 | 9.2 | 11.6 |
| Total other income | 0.4 | 0.5 | 0.4 | 0.4 |
| Income before provision for income taxes | 12.4 | 14.4 | 9.6 | 12.0 |
| Provision for income taxes | 3.0 | 3.2 | 2.3 | 2.6 |
| Net income | 9.4% | 11.2% | 7.3% | 9.4% |

12

**Three Months Ended September 30, 2021 Compared With Three Months Ended September 30, 2020, and Six Months Ended September 30, 2021 Compared With Six Months Ended September 30, 2020**

### COVID-19

We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our work place. The Company has been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain, however we have experienced some delays in the delivery of some inventory items. See risk factor “*The recent outbreak of the COVID-19 global pandemic and related government, private sector and individual consumer responsive actions may adversely affect our business operations, employee availability, financial performance, liquidity and cash flow for an unknown period of time”* in Part I, Item 1A of our Form 10-K for the year ended March 31, 2021.

### Sales

Sales decreased by approximately $8.1 million, or 10.7%, to approximately $67.4 million for the quarter ended September 30, 2021, from approximately $75.4 million for the quarter ended September 30, 2020. For the six months ended September 30, 2021, sales decreased by approximately $24.9 million, or 14.5%, to approximately $146.7 million compared to $171.6 million for the six months ended September 30, 2020. The decrease in sales for the quarter and six months ended September 30, 2021 was primarily due to decreased new orders and reorder sales. Sales for the quarter and six months ended September 30, 2021 were impacted by a much more competitive environment, and a crowded advertising market which had substantially higher advertising costs compared to the same periods in the prior year. Veterinary visits increased during the quarter compared to being down during the prior year, due to the pandemic. We believe the increase in veterinary visits was primarily due to pet owners needing to visit their veterinarian for their pets’ annual exam in order to renew their prescriptions, as many veterinarians were closed due to the pandemic. The Company acquired approximately 65,000 new customers for the quarter ended September 30, 2021, compared to approximately 96,000 new customers for the same period the prior year. For the six months ended September 30, 2021 the Company acquired approximately 157,000 new customers, compared to 282,000 new customers for the six months ended September 30, 2020. The following chart illustrates sales by various sales classifications:

*Three Months Ended September 30,*

|  |  |  |  |  |
| --- | ---: | ---: | ---: | ---: |
| **Sales (In thousands)** | **2021%** | **2020%** | **$ Variance** | **% Variance** |
| Reorder Sales | $62,016 92.0% | $67,761 89.8% | $(5,745) | -8.5% |
| New Order Sales | 5,370 8.0% | 7,675 10.2% | (2,305) | -30.0% |
| Total Net Sales | $67,386 100.0% | $75,436 100.0% | $(8,050) | -10.7% |
| Internet Sales | $55,961 83.0% | $62,697 83.1% | $(6,736) | -10.7% |
| Contact Center Sales | 11,425 17.0% | 12,739 16.9% | (1,314) | -10.3% |
| Total Net Sales | $67,386 100.0% | $75,436 100.0% | $(8,050) | -10.7% |

*Six Months Ended September 30,*

|  |  |  |  |  |
| --- | ---: | ---: | ---: | ---: |
| **Sales (In thousands)** | **2021%** | **2020%** | **$ Variance** | **% Variance** |
| Reorder Sales | $132,953 90.6% | $148,186 86.3% | $(15,233) | -10.3% |
| New Order Sales | 13,745 9.4% | 23,454 13.7% | (9,709) | -41.4% |
| Total Net Sales | $146,698 100.0% | $171,640 100.0% | $(24,942) | -14.5% |
| Internet Sales | $122,408 83.4% | $144,208 84.0% | $(21,800) | -15.1% |
| Contact Center Sales | 24,290 16.6% | 27,432 16.0% | (3,142) | -11.5% |
| Total Net Sales | $146,698 100.0% | $171,640 100.0% | $(24,942) | -14.5% |

13

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. No guarantees can be made that sales will grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications. For the quarters ended June 30, September 30, December 31, and March 31 of Fiscal 2021, the Company’s sales were approximately 31%, 25%, 21%, and 23%, respectively as a percentage of annual sales.

### Cost of sales

Cost of sales decreased by approximately $4.2 million, or 8.0%, to approximately $48.2 million for the quarter ended September 30, 2021, from approximately $52.4 million for the quarter ended September 30, 2020. For the six months ended September 30, 2021, cost of sales decreased by approximately $16.1 million, or 13.2%, to approximately $105.7 million compared to $121.8 million for the same period in the prior year. The cost of sales decreases can be directly related to the decreases to sales during the three and six months ended September 30, 2021. As a percentage of sales, cost of sales was 71.5% and 69.5% for the quarters ended September 30, 2021 and 2020, respectively, and for the six months ended September 30, 2021 and 2020 cost of sales was 72.1% and 71.0%, respectively. The cost of sales percentage for the quarter and six months were adversely impacted due to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates.

### Gross profit

Gross profit decreased by approximately $3.8 million, or 16.7%, to approximately $19.2 million for the quarter ended September 30, 2021, from approximately $23.0 million for the quarter ended September 30, 2020. For the six months ended September 30, 2021 gross profit decreased by approximately $8.8 million, or 17.8%, to approximately $41.0 million, compared to $49.8 million for the same period in the prior year. The decrease in gross profit is directly related to a decrease in sales during the quarter and six months ended September 30, 2021. Gross profit as a percentage of sales was 28.5% and 30.5% for the three months ended September 30, 2021 and 2020, respectively, and for the six months ended September 30, 2021 and 2020, gross profit as a percentage of sales was 27.9% and 29.0%, respectively. The gross profit percentage decreases for the quarter and the six months can also be attributed to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates.

### General and administrative expenses

General and administrative expenses increased by approximately $149,000, or 2.2%, to approximately $6.9 million for the quarter ended September 30, 2021, from approximately $6.8 million for the quarter ended September 30, 2020. The increase in general and administrative expenses for the quarter ended September 30, 2021 was primarily due to the following: a $114,000 increase to other expenses, relating to increasing a state sales tax related accrual during the period; an $80,000 increase in professional fees; and a $24,000 increase in travel related expenses, offset by a net decrease of $69,000 which included decreases in bank service fees and property expenses. For the six months ended September 30, 2021, general and administrative expenses increased by approximately $436,000, or 3.0%, to approximately $14.9 million, compared to $14.6 million for the same period the prior year. The increase in general and administrative expenses for the six months ended September 30, 2021 was primarily due to the following: a $418,000 increase in professional fees, with $260,000 related to brand and marketing consultation; a $114,000 increase to other expenses, relating to increasing a state sales tax related accrual during the period; offset by a net decrease of $96,000 primarily related to a reduction in bank service fees due to a decrease in sales.

### Advertising expenses

Advertising expenses decreased by approximately $1.7 million, or 33%, to approximately $3.4 million for the quarter ended September 30, 2021, from approximately $5.1 million for the quarter ended September 30, 2020. For the six months ended September 30, 2021, advertising expenses decreased by approximately $3.1 million, or 22%, to approximately $11.1 million compared to advertising expenses of approximately $14.2 million for the six months ended September 30, 2020. The decrease in advertising expenses for the three months ended September 30, 2021 was due to management’s decision to reduce advertising spend in the quarter. During the quarter and six months ended September 30, 2021, while the pandemic was abating and many retail stores were re-opening, the advertising market was rapidly recovering with demand driving up advertising prices dramatically. As a result, our advertising for the three and six months ended September 30, 2021 was less effective in its ability to attract new customers.

The advertising costs of acquiring a new customer, defined as advertising expense divided by new customers acquired, was relatively flat, approximately $54 for the quarters ended September 30, 2021 and 2020, and $71 for the six months ended September 30, 2021 compared to $50 for the six months ended September 30, 2020. The increase for the six month ended September 30, 2021, was due to a substantial increase in advertising prices. The advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, advertising spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future new order sales, whereas a less favorable advertising environment may negatively impact future new order sales. As a percentage of sales, advertising expense was 5.1% and 6.8% for the quarters ended September 30, 2021 and 2020, and for the six months ended September 30, 2021 and 2020 advertising expense was 7.6% and 8.3%, respectively. The decrease in advertising expense as a percentage of total sales for the three and six months ended September 30, 2021 can be mainly attributed to decreased sales and a reduction in advertising expense. The advertising percentage will fluctuate quarter to quarter due to seasonality, advertising availability, and return on investment requirements.

### Depreciation

Depreciation expense increased by approximately $87,000 to approximately $694,000 for the quarter ended September 30, 2021, from approximately $607,000 for the quarter ended September 30, 2020. For the six months ended September 30, 2021 and 2020 depreciation expense was approximately $1.3 and $1.2 million, respectively. The increase to depreciation expense for the quarter and six months ended September 30, 2021 can be attributed to new property and equipment additions during the same periods.

### Other income

Other income decreased by approximately $160,000 to approximately $244,000 for the quarter ended September 30, 2021 from approximately $404,000 for the quarter ended September 30, 2020. For the six months ended September 30, 2021 other income decreased by approximately $136,000 to approximately $613,000 compared to approximately $749,000 for the same period in the prior year. The decrease to other income for the quarter and six months ended September 30, 2021 is primarily related to decrease in advertising income. Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $28.7 million remaining as of September 30, 2021, on any quarterly dividend payment or on its operating activities.

### Provision for income taxes

For the quarters ended September 30, 2021 and 2020, the Company recorded an income tax provision of approximately $2.0 million and $2.5 million, respectively, and for the six months ended September 30, 2021 and 2020, the Company recorded an income tax provision of approximately $3.3 million and $4.5 million, respectively. The decrease in the income tax provision for the three and six months ended September 30, 2021 is related to a decrease in operating income during the periods. The effective tax rate for the quarter ended September 30, 2021 was approximately 23.8%, compared to 22.6% for the quarter ended September 30, 2020, and the effective tax rate for the six months ended September 30, 2021 was approximately 23.7% compared to 21.7% for the six months ended September 30, 2020. The increase to the effective tax rate for the quarter ended September 30, 2021 can be attributed to more non-deductible expenses in the September quarter. The increase to the effective tax rate for the six months ended September 30, 2021 can be attributed to the Company receiving a one-time state income tax refund of $285,000 in the June 2020 quarter.

### Liquidity and Capital Resources

The Company’s working capital at September 30, 2021 and March 31, 2021 was $117.2 million and $116.3 million, respectively. The approximately $900,000 increase in working capital was primarily attributable to income generated by operations and a reduction to accounts payable, offset by dividends paid in the period. Net cash provided by operating activities was $1.1 million and $15.2 million for the six months ended September 30, 2021 and 2020, respectively. This change is primarily due to a reduction in net income and a decrease in accounts payable, offset by a decrease in inventories. Net cash used in investing activities was $972,000 for the six months ended September 30, 2021, compared to net cash used in investing activities of $1.2 million for the six months ended September 30, 2020. This change in investing activities is related to an increase in property and equipment additions in the six months ended September 30, 2021. Net cash used in financing activities was $12.3 million for the six months ended September 30, 2021, compared to $11.4 million for the same period in the prior year. The change to financing activities relates to an increase in the dividend paid in the six months ended September 30, 2021, compared to the prior period. At September 30, 2021, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

Subsequent to September 30, 2021, on October 25, 2021 our Board of Directors declared a $0.30 per share dividend. The Board of Directors established a November 8, 2021 record date and a November 19, 2021 payment date. Depending on future market conditions the Company may utilize its cash and cash equivalents on the remaining balance of its current share repurchase plan, on dividends, or on its operating activities.

At September 30, 2021, the Company had no material outstanding lease commitments. We are not currently bound by any long- or short-term agreements for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Presently, we have approximately $1.0 million forecasted for capital expenditures for the remainder of fiscal 2022, the majority of which will be invested in our e-commerce platform to better service our customers, which will be funded through cash from operations. The Company’s primary source of working capital is cash from operations. The Company presently has no need for alternative sources of working capital, and has no commitments or plans to obtain additional capital.

### Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements at September 30, 2021.

### Cautionary Statement Regarding Forward-Looking Information

Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this quarterly report. When used in this quarterly report on Form 10-Q, "PetMed Express," "1-800-PetMeds," "PetMeds," "PetMed," "PetMeds.com," “1800PetMeds.com,” "PetMed.com," "PetMed Express.com," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and our subsidiaries.

## Market risk

As filed, 1,600 characters.

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash and cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At September 30, 2021, we had $106.6 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our cash and cash equivalents to high-quality cash and cash equivalents with both short- and long-term maturities. We do not hold any derivative financial instruments that could expose us to significant market risk. At September 30, 2021, we had no debt obligations.

## Controls and procedures

As filed, 1,470 characters.

Evaluation of Disclosure Controls and Procedures

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15 promulgated under the Securities Exchange Act of 1934, as amended) as of the quarter ended September 30, 2021, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective such that the information relating to our Company, including our consolidated subsidiaries, required to be disclosed by the Company in reports that it files or submits under the Exchange Act: (1) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 386 characters.

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our Annual Report on Form 10-K for Fiscal Year 2021 for additional information concerning these and other uncertainties that could negatively impact the Company.

Filed Nov 2, 2021.
Source: SEC EDGAR, the filing index for accession 0001437749-21-024890. Last ingested by Listed: Nov 13, 2026, 14:26 ET. No prices; not investment advice.
